Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, non-fatal heart attack, or non-fatal stroke – with the benefits ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first 6 months, and for some ...

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first six months, and for some ...

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.

Together, with the established benefits of semaglutide for diabetes, obesity and heart disease, this is a major step forward for patients with MASH, who often have obesity and diabetes and are at ...